Distribution and Cellular Uptake of PEGylated Polymeric Particles in the Lung Towards Cell-Specific Targeted Delivery
- 23 May 2015
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 32 (10) , 3248-3260
Abstract
Purpose We evaluated the role of a poly(ethylene glycol) (PEG) surface coating to increase residence times and alter the cellular fate of nano- and microparticles delivered to the lung. Methods Three sizes of PRINT hydrogel particles (80 × 320 nm, 1.5 and 6 μm donuts) with and without a surface PEG coating were instilled in the airways of C57/b6 mice. At time points of 1, 7, and 28 days, BALF and whole lungs were evaluated for the inflammatory cytokine Il-6 and chemokine MIP-2, histopathology, cellular populations of macrophages, dendritic cells (DCs), and granulocytes, and particulate uptake within these cells through flow cytometry, ELISAs, and fluorescent imaging. Results Particles of all sizes and surface chemistries were readily observed in the lung with minimal inflammatory response at all time points. Surface modification with PEGylation was found to significantly increase lung residence times and homogeneous lung distribution, delaying macrophage clearance of all sizes, with the largest increase in residence time observed for 80 × 320 nm particles. Additionally, it was observed that DCs were recruited to the airway following administration of unPEGylated particles and preferentially associated with these particles. Conclusions Pulmonary drug delivery vehicles designed with a PEG surface coating can be used to delay particle uptake and promote cell-specific targeting of therapeutics.Keywords
This publication has 51 references indexed in Scilit:
- Microfabricated Engineered Particle Systems for Respiratory Drug Delivery and Other Pharmaceutical ApplicationsJournal of Drug Delivery, 2012
- Nanomedicine in pulmonary deliveryInternational Journal of Nanomedicine, 2009
- Targeted delivery of nanoparticles for the treatment of lung diseasesAdvanced Drug Delivery Reviews, 2008
- Design of nanoparticle-based dry powder pulmonary vaccinesExpert Opinion on Drug Delivery, 2007
- Particle Engineering for Pulmonary Drug DeliveryPharmaceutical Research, 2007
- Inhaling medicines: delivering drugs to the body through the lungsNature Reviews Drug Discovery, 2007
- Alveolar macrophages are a primary barrier to pulmonary absorption of macromoleculesAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Evolution of dry powder inhaler design, formulation, and performanceRespiratory Medicine, 2002
- Inhalable Microparticles Containing Drug Combinations to Target Alveolar Macrophages for Treatment of Pulmonary TuberculosisPharmaceutical Research, 2001
- Pulmonary and thoracic macrophage subpopulations and clearance of particles from the lung.Environmental Health Perspectives, 1992